Related Experiment Video
Updated: Jun 7, 2025
Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
[Current status of diagnosis and treatment and progress in drug research and development for hepatitis D]
1Institute of Peking University Hepatology, Peking University People's Hospital, Infectious Disease and Hepatology Center of Peking University People's Hospital, Beijing100044, China.
Insights
Chronic hepatitis D (HDV) is a severe liver disease often overlooked. Implementing reflex testing models can significantly improve HDV screening rates, aiding diagnosis and treatment.
Area of Science:
- Hepatology
- Virology
- Public Health
Background:
- Chronic hepatitis D, a severe liver disease caused by hepatitis D virus (HDV) and hepatitis B virus (HBV) co-infection, often progresses rapidly with a poor prognosis.
- Despite its severity, chronic hepatitis D receives limited attention from the public and clinicians, leading to low screening rates due to detection method limitations and lack of screening systems.
- Previous treatment methods have shown inadequate effectiveness, further diminishing enthusiasm for screening, diagnosis, and treatment.
Purpose of the Study:
- To review the current status of detection methods, screening, diagnosis, and treatment for chronic hepatitis D.
- To highlight recent advancements in anti-HDV drug research and development.
- To explore effective strategies for increasing HDV screening rates globally, referencing successful models.
Main Methods:
- Review of existing literature on hepatitis D virus (HDV) detection, screening protocols, and therapeutic interventions.
- Analysis of clinical trial data and commercialization status of new anti-HDV drugs.
- Examination of the effectiveness of the reflex test model in enhancing HDV screening rates in various international settings.
Main Results:
- Recent progress in anti-HDV drug development includes drugs entering clinical trials and some gaining commercial approval globally.
- The reflex test model has demonstrated effectiveness in increasing HDV screening rates, serving as a valuable reference for other regions.
- Despite advancements, HDV screening rates remain low globally due to various systemic and diagnostic challenges.
Conclusions:
- Increased attention and improved screening strategies are crucial for managing chronic hepatitis D.
- The reflex testing model offers a promising approach to enhance HDV screening rates and improve patient outcomes.
- Continued research and development of effective anti-HDV therapies are essential for addressing this severe liver disease.
Abstract:
Chronic hepatitis D is a kind of severe viral hepatitis caused by co-infection with hepatitis D virus (HDV) and hepatitis B virus (HBV) or infection with HDV on the ground of HBV infection. Patients with hepatitis D who are infected with HBV often have faster disease progression and a worse prognosis. However, the public and clinicians have always paid little attention to chronic hepatitis D. Coupled with the limitations of detection methods and the absence of a screening system, the HDV screening rate in various regions of the world is at a low level. Consequently, the enthusiasm for screening, diagnosis, and treatment has been further reduced by the inadequate effectiveness of previous treatment methods. In recent years, progress has been made in the research and development of anti-HDV drugs, and a variety of drugs have already entered the clinical trial stage, and some have already been approved for commercialization in specific parts of the world. In this context, the world is also actively exploring effective ways to increase the HDV screening rate. The reflex test model can effectively raise the HDV screening rate and serve as a reference for HDV screening in other countries and regions, as demonstrated by studies conducted in the United Kingdom, France, and Spain, among others. This article will review the detection methods, screening, diagnosis, and treatment current status, as well as the progress in drug research and development, in order to help clinical physicians understand chronic HDV diagnosis and treatment.
Related Concept Videos
01:11Clinical Trials: Overview
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:26Drug Discovery: Overview
01:28Preclinical Development: Overview
01:25Drug Regulation